2 top leaders at Google’s $4.5 billion venture arm want to transform how new drugs get made to boost their entire portfolio

David Schenkein and Krishna Yeshwant, who lead the life sciences team at GV, formerly Google Ventures, want to upend the costly, time-consuming process of making new drugs.  They spoke with Business Insider about how they’re approaching the space, which is so stuck in the past that they say any aspect of it is in scope right now.   They’re not the only ones with this interest. But Schenkein and Yeshwant believe they’re in a unique

Continue reading...